Literature DB >> 27165824

Long-term outcomes of end-stage kidney disease for patients with lupus nephritis.

Lei Zhang1, Gavin Lee2, Xusheng Liu3, Elaine M Pascoe4, Sunil V Badve2, Neil C Boudville5, Philip A Clayton6, Carmel M Hawley2, John Kanellis7, Stephen P McDonald8, Chen Au Peh9, Kevan R Polkinghorne10, David W Johnson11.   

Abstract

Patient outcomes in end-stage kidney disease (ESKD) secondary to lupus nephritis have not been well described. To help define this we compared dialysis and transplant outcomes of patients with ESKD due to lupus nephritis to all other causes. All patients diagnosed with ESKD who commenced renal replacement therapy in Australia and New Zealand (1963-2012) were included. Clinical outcomes were evaluated in both a contemporary cohort (1998-2012) and the entire 50-year cohort. Of 64,160 included patients, 744 had lupus nephritis as the primary renal disease. For the contemporary cohort of 425 patients with lupus nephritis, the 5-year dialysis patient survival rate was 69%. Of 176 contemporary patients with lupus nephritis who received their first renal allograft, the 5-year patient, overall renal allograft, and death-censored renal allograft survival rates were 95%, 88%, and 93%, respectively. Patients with lupus nephritis had worse dialysis patient survival (adjusted hazard ratio 1.33, 95% confidence interval 1.12-1.58) and renal transplant patient survival (adjusted hazard ratio 1.87, 95% confidence interval 1.18-2.98), but comparable overall renal allograft survival (adjusted hazard ratio 1.19, 95% confidence interval 0.84-1.68) and death-censored renal allograft survival (adjusted hazard ratio 1.05, 95% confidence interval 0.68-1.62) compared with ESKD controls. Similar results were found in the entire cohort and when using competing-risks analysis. Thus, the ESKD of lupus nephritis was associated with worse dialysis and transplant patient survival but comparable renal allograft survival compared with other causes of ESKD. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dialysis; disease recurrence; end-stage kidney disease; kidney transplantation; outcomes; renal transplantation; systemic lupus erythematosus

Mesh:

Year:  2016        PMID: 27165824     DOI: 10.1016/j.kint.2016.02.014

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  [Lupus nephritis].

Authors:  S Melderis; T Wiech; C Iking-Konert; O M Steinmetz
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

Review 2.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

3.  A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis.

Authors:  Dong-Ni Chen; Li Fan; Yu-Xi Wu; Qian Zhou; Wei Chen; Xue-Qing Yu
Journal:  Chin Med J (Engl)       Date:  2018-06-05       Impact factor: 2.628

4.  Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.

Authors:  Cristina Pamfil; Zuzanna Makowska; Aurélie De Groof; Gaëlle Tilman; Sepideh Babaei; Christine Galant; Pauline Montigny; Nathalie Demoulin; Michel Jadoul; Selda Aydin; Ralf Lesche; Fiona McDonald; Frédéric A Houssiau; Bernard R Lauwerys
Journal:  Ann Rheum Dis       Date:  2018-07-31       Impact factor: 19.103

Review 5.  Recurrent and de novo Glomerulonephritis After Kidney Transplantation.

Authors:  Wai H Lim; Meena Shingde; Germaine Wong
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

6.  Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry.

Authors:  Wen-Ling Yang; Bhadran Bose; Lei Zhang; Megan Mcstea; Yeoungjee Cho; Magid Fahim; Carmel M Hawley; Elaine M Pascoe; David W Johnson
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

7.  Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation.

Authors:  Joel Swai; Xiexiong Zhao; Julie-Raisa Noube; Gui Ming
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

8.  Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis.

Authors:  Chang Seong Kim; Ansuja Pulickal Mathew; Arathy Vasukutty; Saji Uthaman; Soo Yeon Joo; Eun Hui Bae; Seong Kwon Ma; In-Kyu Park; Soo Wan Kim
Journal:  J Nanobiotechnology       Date:  2021-04-17       Impact factor: 10.435

Review 9.  Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.

Authors:  Mario E Alamilla-Sanchez; Miguel A Alcala-Salgado; Cesar D Alonso-Bello; Gandhy T Fonseca-Gonzalez
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-12-11

Review 10.  Prediction of prognosis and renal outcome in lupus nephritis.

Authors:  Ioannis Parodis; Farah Tamirou; Frédéric A Houssiau
Journal:  Lupus Sci Med       Date:  2020-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.